
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc. is positioned favorably in the regenerative medicine sector through its expanding portfolio, particularly with Apligraf experiencing a fourfold increase in average selling price (ASP), establishing itself as a leader in efficacy among its product offerings. Despite facing mixed performance due to shifting market dynamics and potential changes in reimbursement structures, the company has demonstrated ongoing improvements in unit volumes, which indicates a trajectory towards stronger quarterly growth in the near future. Additionally, the adjustment in reimbursement rates for 2026, increasing slightly from the proposal, reflects a resilient pricing environment that could enhance the company's valuation and financial performance moving forward.
Bears say
Organogenesis Holdings Inc. has experienced a significant decline in its share price, dropping approximately 35% due to weaker-than-expected guidance for FY26, primarily driven by reimbursement policy changes in the Advanced Wound Care market. The company anticipates a substantial year-over-year decline of roughly 50% in 1Q26 as it undertakes measures to address product sizing waste and excess inventory. Additionally, potential downside risks include subpar growth in its PuraPly product line, adverse Medicare pricing developments, and competitive challenges related to regulatory integration and new product uptake, further contributing to a cautious outlook for the company.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares